Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • elinzanetant

    - PMLiVE

    Lilly announces new study data on Inluriyo in metastatic breast cancer

    The five-year survival rate for metastatic breast cancer is 30%

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Medherant announces positive phase 1 results for testosterone patch for women

    University of Warwick spin-out develops first-in-class testosterone patch to support women through menopause

    - PMLiVE

    Innovation in Action at AAFP FMX 2025

    This year, Medscape Education is redefining the live learning experience at AAFP FMX 2025. With 8 groundbreaking, accredited symposia, we are proud to be at the heart of the meeting,...

    Medscape Education

    - PMLiVE

    Lilly reports survival benefit with Verzenio in high-risk early breast cancer

    The findings are based on Lilly’s phase 3 monarchE trial

    - PMLiVE

    Advertising For Women’s Health: Breaking Taboos and Driving Change

    Our strategist Stephanie Goley, MSc, PhD takes a fascinating look at how advertising is breaking down stigmas around areas of women's health such as menstruation and menopause - and helping...

    11 London

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    - PMLiVE

    Researchers uncover promising treatment approach for inherited breast cancer

    The study evaluated chemotherapy followed by a targeted cancer drug in patients before surgery

    - PMLiVE

    Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

    Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

    Around one in three patients with early-stage breast cancer are considered high risk

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links